ClinicalTrials.gg
CompletedNCT01233960Updated Mar 11, 2026

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

A Phase 3 interventional study of Prochymal® in Crohn's Disease, sponsored by Mesoblast, Inc.. Completed at 20 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Mesoblast, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2014, 12 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
240th of 528
73 · median 60
Started
2010
with 20 others
Phase 3
124 of 660
21 open now
Registered
163rd of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 240th largest by enrollment of the 528 interventional ones that give a count, is one of 21 that started in 2010, is one of 124 in phase 3, and was the 163rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.

Read the detailed description

Participants will receive infusions of PROCHYMAL on Day 42, Day 84, and Day 126 after initial infusion of PROCHYMAL in Protocol 603. Each infusion will contain 200 million cells. As participants will be required to be in Protocol 603 during the entire duration of their participation in Protocol 611, all concomitant medication and safety information will be monitored by Protocol 603 and the combination of data from the two protocols.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
  • Adult Stem Cell Therapy
  • inflammation of the gastrointestinal tract
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have qualified for, enrolled in, and provided written form (ICF) and authorization for use and disclosure of protected health information (PHI) for Protocol 603 after the August 3, 2010.
  • Participant successfully completed all screening assessments in Protocol 603 as required by Protocol 603.
  • Participant successfully completed the full course of each of the four infusions of agent on Days 0, 3, 7, and 14 of Protocol 603 after August 3, 2010.
  • Participant must enroll in Protocol 611 on or before the 45th day after first infusion in Protocol 603.
  • Participant must provide written ICF and authorization for use and disclosure of PHI for Protocol 611.

Exclusion criteria

Exclusion Criteria:

  • Participant is unwilling or unable to adhere to requirements of Protocol 611.
  • Participant had confirmed respiratory distress during a PROCHYMAL infusion in any prior PROCHYMAL study.
  • Participant had a serious adverse event in any previous PROCHYMAL study that was deemed by the principal investigator of that study to be possibly or probably related to PROCHYMAL and also that was within 48 h after a PROCHYMAL infusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Prochymal®

    Infusions of Prochymal on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.

    Drug: Prochymal®

Interventions

  • PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.

    Also known as: Adult human mesenchymal stem cells, Remestemcel-L

06

What researchers measure

Primary outcomes

  1. Disease remission

    Crohn's Disease Activity Index (CDAI) at or below 150 and increase in IBDQ

    Time frame: 180 Days after first infusion in Protocol 603

Secondary outcomes

  1. Disease Improvement

    CDAI response to treatments is defined as a CDAI of 150 or below, or a reduction in CDAI of at least 100 points.

    Time frame: 180 Days after first infusion in Protocol 603

  2. Improvement in Quality of Life (IBDQ)

    IBDQ response to treatment is defined as IBDQ of 170 or above, or an increase in IBDQ of at least 16 points.

    Time frame: 180 Days after first infusion in Protocol 603

  3. Number of Adverse events as a measure of safety

    Time frame: 180 Days after first infusion in Protocol 603

  4. Infusional toxicity as a measure of safety and tolerability

    Infusional toxicity will be evaluated by continuously monitoring the subject's vital signs and O2 saturation by pulse oximetry from the time of PROCHYMAL administration until two hours after infusion is complete.

    Time frame: 180 Days after first infusion in Protocol 603

07

Study locations

20 sites
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • University of Chicago
    Chicago, Illinois 60611, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • University of Maryland, Baltimore
    Baltimore, Maryland 21201, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Saint Louis Center for Clinical Research
    St Louis, Missouri 63128, United States
  • St. Louis Center for Clinical Studies
    St Louis, Missouri 63128, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Weill Cornell Medical College
    New York, New York 10028, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Gastroenterology Center of the Midsouth, PC
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • McGuire Research Institute
    Richmond, Virginia 23249, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria, Australia
  • University of Otago
    Christchurch, New Zealand
  • Waikato Hospital
    Hamilton, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Sep 2014, 45 months.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 45 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2010
First posted
Nov 3, 2010
StartActual
Nov 29, 2010
Primary completionActual
Sep 15, 2014
CompletionActual
Sep 15, 2014
Results delay requested
Dec 3, 2021
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01233960
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Nov 3, 2010
Start date
Nov 29, 2010
Primary completion
Sep 15, 2014
Completion
Sep 15, 2014
Last update
Mar 11, 2026

Study contacts

Christopher James, PA
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion